Is Bristol Myers Squibb Co undervalued or overvalued?

Where Bristol Myers Squibb Co (BMY) trades across 21 valuation metrics, from price-to-sales and forward P/E to book and cash-flow multiples, each ranked against its own five-year history rather than a broad sector average, so you can see whether it is genuinely cheap or expensive on its own terms. Information, not advice.